Moving From Early Phase To Phase 2 Studies: How A CRO Can Help

Having your drug candidate make it out of preclinical and early phase studies is a major milestone – as many oncology candidates don’t make it past Phase 1. But now what? How do you transition from early phase studies to commercialization?

To take this step in the drug development journey to commercialization, biotech companies often engage a contract research organization (CRO) with the required experience and capabilities for running successful clinical trials. A partner with global knowledge can help biotech companies define and implement the best strategies and pathways to move their therapy forward rapidly and cost-effectively, giving them a tremendous competitive advantage.